Provided by Tiger Fintech (Singapore) Pte. Ltd.

Denali Therapeutics Inc.

14.95
-1.7400-10.43%
Post-market: 14.950.00000.00%18:14 EDT
Volume:1.74M
Turnover:26.60M
Market Cap:2.17B
PE:-5.82
High:16.53
Open:16.36
Low:14.88
Close:16.69
Loading ...

Denali Therapeutics Inc - Key Secondary Endpoints Not Statistically Different at Week 24

THOMSON REUTERS
·
07 Jan

Denali Therapeutics Inc - Dnl343 Found to Be Safe and Well Tolerated

THOMSON REUTERS
·
07 Jan

Denali Therapeutics Announces Topline Results for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial

THOMSON REUTERS
·
07 Jan

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

GlobeNewswire
·
07 Jan

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Benzinga
·
04 Jan

Denali Therapeutics Initiated at Outperform by William Blair

Dow Jones
·
03 Jan

Denali Therapeutics upgraded to Buy from Hold at Stifel

TipRanks
·
17 Dec 2024

Stifel Nicolaus Upgrades Denali Therapeutics to Buy From Hold, Raises Price Target to $37 From $28

MT Newswires Live
·
16 Dec 2024

We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely

Simply Wall St.
·
09 Dec 2024

Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?

Zacks
·
07 Dec 2024

Denali Starts Dosing in Phase II Parkinson's Disease Study

Zacks
·
06 Dec 2024

Denali Therapeutics announces first patient dosed in Phase 2a study of BIIB122

TIPRANKS
·
05 Dec 2024

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of Lrrk2 Inhibitor, Biib122, in Lrrk2-Associated Parkinson’s Disease

THOMSON REUTERS
·
05 Dec 2024

Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging

Zacks
·
08 Nov 2024

Denali Therapeutics (DNLI) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
07 Nov 2024

Denali Therapeutics Inc : Wedbush Raises Target Price to $33 From $30

THOMSON REUTERS
·
07 Nov 2024